Intratio
Quantitative Research
Skip to main content
AI Market Summary
Loading market intelligence...
  • Sign in
    My account
    Logout
AI 90-DAY FORECAST
NEUTRAL SIGNAL
██.█% Sign up free to reveal

Generate Biomedicines, Inc. (GENB) AI Forecast

Our AI analyzed Generate Biomedicines, Inc.. Create a free account and follow it to see the 90-day price prediction.

✓ Free account • ✓ 30-day free trial

$GENB Neutral Signal Full forecast available
Sign Up Free

Generate Biomedicines, Inc. (GENB) Stock Forecast 2025

Generate Biomedicines, Inc. (GENB) AI Stock Price Forecast & Investment Analysis

Generate Biomedicines, Inc. Stock Price Chart and Technical Analysis

Loading chart...

Generate Biomedicines, Inc. (GENB) - Comprehensive Stock Analysis & Investment Research

Deep dive into Generate Biomedicines, Inc.'s business profile, financial performance, AI predictions, and competitive positioning to make informed investment decisions.

Analysis updated on August 5, 2026, 4:18 p.m. (UTC)

Generate Biomedicines, Inc. Investment Summary

When evaluating whether Generate Biomedicines, Inc. (GENB) represents a compelling investment opportunity, investors must consider multiple factors including the company's financial health, market position, growth prospects, and what our AI-powered predictive models suggest about its near-term price trajectory.

Company Profile

Generate Biomedicines, Inc. (GENB) operates within the Life Sciences sector, specifically in the Pharmaceutical Preparations industry. . With a market capitalization of $2 billion, the company is a small-cap stock that may offer higher growth potential but also carries higher volatility.

Financial Performance Analysis

Our comprehensive financial analysis covers Generate Biomedicines, Inc.'s revenue, profitability metrics, balance sheet strength, and cash flow generation...

AI Price Predictions

Get AI-powered 7-day, 30-day and 90-day price forecasts for Generate Biomedicines, Inc. along with confidence scores and detailed analysis...

Investment Considerations

Expert analysis of whether Generate Biomedicines, Inc. is suitable for your investment objectives, risk tolerance, and time horizon...

Continue Reading Full Analysis

Get the complete investment breakdown for Generate Biomedicines, Inc.

Sign Up Free
Corporate Identity

Generate Biomedicines, Inc. (Stock Symbol: GENB) is a prominent company operating within the Life Sciences sector, with a specific focus on the Pharmaceutical Preparations industry. The company's shares are publicly traded on the Nasdaq exchange.

Leadership & Workforce

Detailed information about Generate Biomedicines, Inc.'s leadership team, workforce size, and organizational structure...

Market Classification

Market capitalization analysis and stock classification (mega-cap, large-cap, mid-cap, small-cap) for Generate Biomedicines, Inc....

Sector & Industry Analysis

In-depth sector dynamics and industry context for Generate Biomedicines, Inc....

Unlock Full Company Profile

Get complete details about Generate Biomedicines, Inc.

Sign Up Free
Revenue & Growth Analysis
Profitability Metrics

Net profit margin, gross margin, and operating margin analysis for Generate Biomedicines, Inc....

Market Valuation

P/E ratio, price-to-book, and valuation multiples for Generate Biomedicines, Inc....

Return Metrics

Return on equity (ROE), return on assets (ROA), and capital efficiency for Generate Biomedicines, Inc....

Unlock Financial Analysis

Get complete financial metrics for Generate Biomedicines, Inc.

Sign Up Free
AI ANALYSIS AVAILABLE

Unlock Generate Biomedicines, Inc.'s AI Price Forecast

Join 10,000+ investors using our 67%+ accurate AI predictions

4,000+ Stocks Analyzed
67%+ Accuracy Rate
Daily Updates
Start 30-Day Free Trial →

✓ 30-day free trial • ✓ Cancel anytime

Strategic Market Position

Generate Biomedicines, Inc. strategically competes in the highly dynamic Pharmaceutical Preparations marketplace. As a small-cap company, it represents an emerging market participant with potentially significant growth opportunities. Small-caps often offer greater growth potential as they capture market share and scale their operations, though this comes with higher risk and volatility. Success at this stage can lead to substantial returns for early investors who identify winning business models.

Industry Competitive Landscape

Generate Biomedicines, Inc. competes within the Life Sciences sector, navigating the competitive dynamics and market forces specific to this industry. The company's competitive position depends on its ability to differentiate through product quality, cost efficiency, customer relationships, or other strategic advantages relevant to its specific market segment.

Operational Efficiency
Financial Strength & Leverage

Current ratio of 9.17 demonstrates strong short-term liquidity with current assets significantly exceeding current liabilities. This provides a substantial buffer for meeting near-term obligations and handling unexpected financial needs.

Generate Biomedicines, Inc. (GENB) Fundamental Analysis & Insider Trading Data (Quarterly Financial Reports)

Comprehensive quarterly financial data, earnings trends, insider transactions, and institutional holdings for Generate Biomedicines, Inc. stock analysis.

Deep dive into Generate Biomedicines, Inc.'s financial health, valuation metrics, and operational efficiency to make informed investment decisions.

Understanding Valuation Metrics

What these metrics mean: Valuation metrics help determine if Generate Biomedicines, Inc. stock is fairly priced compared to its earnings, assets, and market position.

How to read them: Lower P/E ratios may indicate undervalued stocks, while higher ratios suggest growth expectations. P/B ratio compares market value to book value.

For Generate Biomedicines, Inc.:

P/B Ratio 3.56x
Market Cap $1.83B
EPS $-4.28
Book Value/Share $4.02
Understanding Profitability Metrics

What these metrics mean: These ratios measure how efficiently Generate Biomedicines, Inc. converts revenue into profit and generates returns for shareholders.

How to read them: Higher ROE/ROA indicate better management efficiency. Margin percentages show profit at different operational levels.

For Generate Biomedicines, Inc.: An ROE of -47.7% indicates room for improvement in shareholder value creation.

ROE -47.7%
ROA -39.3%
ROIC -45.2%
Operating Margin -887.5%
Net Margin -850.6%
EBT Margin -853.9%
Tax Rate -0.1%
Understanding Financial Health Metrics

What these metrics mean: These ratios assess Generate Biomedicines, Inc.'s ability to meet short-term obligations and manage debt levels effectively.

How to read them: Current ratio >2 is generally good, Quick ratio >1 shows strong liquidity. Lower D/E ratios indicate conservative debt management.

For Generate Biomedicines, Inc.: A current ratio of 9.17 indicates strong liquidity.

Current Ratio 9.17x
D/E Ratio 0.22x
Financial Leverage 1.22x
Working Capital $477M
Understanding Cash Flow Metrics

What these metrics mean: Cash flow metrics reveal Generate Biomedicines, Inc.'s ability to generate cash from operations and fund growth initiatives.

How to read them: Positive operating cash flow is crucial. Free cash flow shows money available for dividends, buybacks, or investments.

For Generate Biomedicines, Inc.:

Operating Cash Flow -$322M
Understanding Operational Efficiency Metrics

What these metrics mean: These ratios measure how effectively Generate Biomedicines, Inc. uses its assets and manages working capital.

How to read them: Higher turnover ratios indicate efficient asset utilization. Shorter collection periods show effective credit management.

For Generate Biomedicines, Inc.:

Understanding Financial Statement Data

What these metrics mean: Key figures from Generate Biomedicines, Inc.'s income statement and balance sheet showing absolute financial performance.

How to read them: Revenue shows business scale, while margins indicate profitability. Balance sheet items reveal financial structure.

For Generate Biomedicines, Inc.:

Income Statement
Operating Income -$256M
Net Income -$245M
R&D Expense $231M
Balance Sheet Highlights (% Of Assets)
Total Current Assets 535%
Cash & Short-term Investments 161%
Total Liabilities 111%
Short-term Debt 51%
Dividend & Shareholder Information
Shares Outstanding 128M
Growth Metrics (YoY)
Net Income Growth -850.6%
EPS Growth -30.0%

Latest Generate Biomedicines, Inc. Stock News & Market Analysis

Breaking news, analyst reports, and market updates affecting Generate Biomedicines, Inc. (GENB) stock price and investment outlook.

📰 Loading...

Generate Biomedicines, Inc. Competitors & Peer Analysis - Life Sciences Sector

Comparative analysis of Generate Biomedicines, Inc. against industry peers and competitors in the Life Sciences sector, featuring AI-powered forecasts and key financial metrics.

Company Ticker Symbol 90-Day AI Forecast Market Cap (USD M) P/E Ratio P/B Ratio
AARD ██% $158M x 1.8x
ABBV ██% $431.12B 68.3x x
ABCL ██% $1.85B x 2.0x
ABEO ██% $388M 5.9x 2.7x
ABT ██% $183.69B 29.3x 3.5x
ABUS ██% $871M 5.4x 3.4x
ABVC ██% $28M x 2.6x
ABVX ██% $9.83B x x
ACAD ██% $4.64B 12.4x 3.7x
ACET ██% $86M x 0.6x
ACRS ██% $835M x 5.8x
ACRV ██% $60M x 0.6x
ACUT ██% $3M x x
ACXP ██% $6M x 0.9x
ADAG ██% $240M x 6.3x
ADCT ██% $140M x x
ADIL ██% $8M x 2.2x
ADTX ██% $3M x x
ADXN ██% $7M x x
AEON ██% $13M x x
AGIO ██% $1.88B x 1.8x
AKBA ██% $354M x 12.9x
AKTX ██% $14M x 1.0x
ALDX ██% $94M x 2.2x
ALKS ██% $8.32B 125.9x 4.6x
ALLR ██% $21M x 3.0x
ALMS ██% $3.39B x 6.0x
ALNY ██% $29.29B 36.5x 21.6x
ALT ██% $597M x 2.1x
ALXO ██% $265M x 1.8x
ALZN ██% $7M x 9.5x
AMLX ██% $2.43B x 8.9x
AMPH ██% $888M 11.2x 1.2x
AMRN ██% $302M x 0.7x
AMRX ██% $5.84B 47.8x x
ANAB ██% $1.60B x 125.6x
ANEB ██% $13M x 1.7x
ANIP ██% $1.66B 18.0x 3.0x
ANIX ██% $116M x 8.0x
ANNX ██% $812M x 4.0x
ANRO ██% $990M x 4.1x
ANTX ██% $214M x 2.6x
ANVS ██% $80M x 25.5x
APLM ██% $39M x x
APRE ██% $7M x 0.2x
APUS ██% $7M x 0.1x
APVO ██% $5M x 0.4x
AQST ██% $465M x x
ARCT ██% $177M x 0.9x
ARDX ██% $1.24B x 8.3x
ARQT ██% $3.25B x 17.2x
ARTL ██% $3M x 0.4x
ARVN ██% $588M 63.2x 1.0x
ARWR ██% $12.64B x 27.2x
ASBP ██% $9M x 2.4x
ASMB ██% $524M x 2.6x
ASND ██% $15.16B x x
ASRT ██% $151M x 2.0x
ATAI ██% $2.66B x 16.6x
ATHE ██% $80M x x
ATNM ██% $25M x 11.0x
ATOS ██% $23M x 0.8x
ATXI ██% $1M x 1.0x
AUPH ██% $1.95B 6.6x 3.4x
AVBP ██% $1.43B x 4.4x
AVIR ██% $376M x 1.6x
AVTX ██% $980M x 14.4x
AXIM ██% $1M x x
AXSM ██% $10.91B x 199.9x
AZTR ██% $2M x 0.2x
BBIO ██% $16.06B x x
BBOT ██% $710M x 1.9x
BCAX ██% $1.71B x 3.3x
BCTX ██% $29M x 1.2x
BCYC ██% $275M x 0.5x
BDPT ██% $30K x x
BDRX ██% $1M x x
BFRG ██% $11M x 2.3x
BFRI ██% $14M x 2.4x
BHC ██% $2.41B x x
BHST ██% $51M x 2.0x
BIOA ██% $497M x 1.3x
BIOE ██% $13M 9.7x x
BIOM ██% $330K x x
BIVI ██% $14M x 0.9x
BIXT ██% $2M x x
BLRX ██% $12M x x
BLTE ██% $6.19B x 8.0x
BMEA ██% $89M x 4.8x
BMRN ██% $11.74B 43.7x 1.9x
BMY ██% $134.55B 14.5x 6.0x
BNTC ██% $430M x 2.4x
BOLD ██% $61M x 0.7x
BOLT ██% $8M x 0.4x
BPTH ██% $2M x x
BQST ██% $2M x x
BRNS ██% $23M x 0.4x
BSPK ██% $10K x x
BTAI ██% $27M x x
BYSI ██% $41M x x
CALC ██% $13M x x
CANF ██% $7M x 1.2x
CAPR ██% $240M x 0.9x
CATX ██% $342M x 1.0x
CBIO ██% $608M x 6.0x
CDT ██% $2M x x
CING ██% $66M x 3.5x
CLCS ██% $65M x x
CLNN ██% $62M x x
CLRB ██% $20M x 6.1x
CLSDQ ██% $1M x x
CLYM ██% $719M x 4.9x
CMMB ██% $12M x 1.0x
CMND ██% $3M x x
CMPS ██% $1.59B x 4.9x
CNBX ██% N/A x x
CNSP ██% $8M x 110.8x
CNTA ██% $6.27B x 12.9x
CNTB ██% $130M x 3.1x
CNTX ██% $57M x 1.1x
COCP ██% $14M x 3.3x
COGT ██% $7.32B x 12.0x
COLL ██% $1.16B 15.5x 3.7x
CORT ██% $11.57B 209.7x 16.4x
COYA ██% $107M x 2.2x
CPHI ██% $48M x 1.3x
CPIX ██% $116M x 5.4x
CPMD ██% $1M x x
CPRX ██% $3.85B 17.4x 3.8x
CRBP ██% $167M x 1.3x
CRMD ██% $590M 3.3x 1.4x
CRNX ██% $8.87B x 7.4x
CRVO ██% $26M x 2.4x
CRVS ██% $1.17B x 4.9x
CTMX ██% $723M x 2.3x
CTNM ██% $596M x 2.5x
CTOR ██% $61M x 1.7x
CTTH ██% $4M x 5.1x
CTXR ██% $17M x 0.3x
CUE ██% $112M x 5.2x
CURX ██% $6M x 0.7x
CVKD ██% $6M x 3.5x
CVSI ██% $4M x 2.6x
CYCN ██% $15M x 2.9x
CYDY ██% $253M x x
CYPH ██% $73M x 0.9x
CYRX ██% $764M 9.6x 1.5x
CYTK ██% $10.67B x x
DARE ██% $20M x 26.6x
DCOY ██% $2M x 0.6x
DERM ██% $175M x 5.7x
DMAC ██% $352M x 7.5x
DMRA ██% $1.85B x 3.6x
DNTH ██% $6.05B x 5.2x
DRMA ██% $4M x 0.7x
DRUG ██% $759M x x
DSGN ██% $826M x 4.1x
DWTX ██% $60M x 0.7x
DYN ██% $4.85B x 6.9x
EBS ██% $392M x 0.8x
EDSA ██% $48M x 4.7x
ELAB ██% $4M x 0.4x
ELAN ██% $12.78B x 2.0x
ELDN ██% $265M x 5.9x
ELTP ██% $389M 8.7x 3.9x
ELTX ██% $83M x x
ELVN ██% $4.37B x 9.6x
EMMA ██% $700K x x
ENLV ██% $36M 0.0x 0.0x
ENSC ██% $6M x x
ENTA ██% $387M x 3.3x
ENVB ██% $7M x 1.3x
EOLS ██% $403M x x
EPRX ██% $426M x 5.2x
EQ ██% $143M x 2.4x
ERAS ██% $6.38B x 16.2x
ERNA ██% $5M x 0.8x
ESPR ██% $799M x x
ETON ██% $1.25B x 41.0x
ETST ██% $29M 6.0x 4.1x
EVFM ██% $930K x x
EVMN ██% $472M x 1.6x
EWTX ██% $4.80B x 9.7x
FBIO ██% $90M 0.7x 0.6x
FBLG ██% $5M x 1.2x
FBRX ██% $1.57B x 37.3x
FHTX ██% $285M x x
FLNA ██% $48M x 0.7x
FTH ██% $657M x 3.8x
FULC ██% $290M x 0.9x
GALT ██% $197M x x
GANX ██% $75M x 5.3x
GCAN ██% $260K x x
GDTC ██% $10M x x
GENB ██% $1.83B x 3.6x
GERN ██% $875M x 3.8x
GHRS ██% $1.81B x x
GLMD ██% $5M x 0.3x
GLSI ██% $210M x 39.9x
GNLX ██% $126M x 5.5x
GNPX ██% $3M x 0.2x
GOSS ██% $89M x x
GOVX ██% $4M x 2.3x
GPCR ██% $3.53B x 2.4x
GRCE ██% $36M x 0.6x
GRI ██% $3M x 0.3x
GRTX ██% $3.38B 22.7x 4646.0x
GSK ██% $103.20B x x
GTBP ██% $12M x 1.6x
GYRE ██% $686M x 6.8x
HCM ██% $2.01B 2.2x 1.6x
HCWB ██% $6M x 1.0x
HELP ██% $575M x x
HEPA ██% $2M x 0.9x
HIND ██% $15M x 2.3x
HOOK ██% $14M x 0.4x
HOWL ██% $20M x 1.2x
HRMY ██% $2.25B 12.4x 2.3x
HRTX ██% $97M x 10.6x
HSTC ██% $99M x 79.9x
HURA ██% $133M x 5.7x
HYFT ██% $64M x x
HYPD ██% $41M x 0.7x
IBIO ██% $73M x 0.9x
IBO ██% $47M x 4.1x
IDYA ██% $3.48B x 2.9x
IFRX ██% $262M x x
IGC ██% $25M x 4.0x
IMMP ██% $57M x x
IMMX ██% $664M x 7.9x
IMNM ██% $2.84B x 4.8x
IMNN ██% $7M x 2.0x
IMRN ██% $9M x x
IMRX ██% $284M x 1.4x
IMUX ██% $191M x 1.3x
INBP ██% $5M x 0.3x
INDP ██% $181M x 145.2x
INDV ██% $4.34B 14.1x x
INM ██% $8M x 1.2x
INO ██% $68M x 11.2x
INSM ██% $21.38B x 30.3x
INTI ██% $14M x x
INVA ██% $1.54B 3.1x 1.2x
IOBTQ ██% $10K x 0.0x
IONS ██% $9.12B x 20.7x
IRD ██% $306M x x
IRON ██% $2.98B x 4.6x
IRWD ██% $709M 6.9x x
ISCO ██% $2M x x
IVA ██% $1.07B x x
IXHL ██% $36M x 0.5x
JAGX ██% $5M x x
JANX ██% $971M x 1.0x
JAZZ ██% $16.53B 17.6x 3.4x
JBIO ██% $1.30B x 4.4x
JNJ ██% $613.72B 29.2x 7.2x
JUNS ██% $5M x x
KALA ██% $14M x 1.3x
KALV ██% $1.38B x x
KAPA ██% $7M x 1.3x
KAYS ██% $210K x x
KMDA ██% $423M x x
KNSA ██% $5.81B 79.6x 9.6x
KPRX ██% $10M x 0.7x
KPTI ██% $44M x x
KROS ██% $203M x 0.8x
KRRO ██% $164M x 1.4x
KTTA ██% $15M x 0.3x
KURA ██% $841M x 7.8x
KYNB ██% $28M 0.2x x
LAB ██% $320M 4.1x 0.6x
LBRX ██% $1.29B x 3.4x
LEGN ██% $3.70B x x
LEXX ██% $9M x 2.0x
LFCR ██% $163M x x
LFVN ██% $86M 10.9x 2.6x
LGND ██% $6.02B 39.2x 6.0x
LGVN ██% $23M x 1.5x
LIANY ██% $12M x 0.1x
LIFD ██% $3M x 0.4x
LIPO ██% $150K x 0.1x
LITS ██% $33M x 0.6x
LIXT ██% $120M x 15.2x
LKFT ██% $1.74B x x
LLY ██% $997.98B 39.5x 32.0x
LNAI ██% $12M x x
LPCN ██% $18M x 0.8x
LQDA ██% $7.80B 349.9x 71.9x
LRMR ██% $427M x 3.4x
LSTA ██% $10M x 1.0x
LTRN ██% $35M x 10.2x
LXRX ██% $1.06B x 5.2x
LYEL ██% $317M x 1.2x
MAIA ██% $83M x 3.0x
MANE ██% $4.48B x 11.5x
MBIO ██% $4M x 0.5x
MBRX ██% $3M x 0.2x
MBX ██% $3.36B x 7.7x
MCRB ██% $50M x 1.9x
MDCX ██% $17M x 13.0x
MDGL ██% $11.72B x 22.4x
MEDS ██% $8M x 0.1x
MGNX ██% $248M x 11.7x
MIRA ██% $28M x 3.0x
MIRM ██% $6.36B x 26.2x
MIST ██% $138M x 3.8x
MLTX ██% $1.53B x 6.0x
MLYS ██% $2.19B x 3.4x
MNKD ██% $1.22B x x
MNOV ██% $64M x 1.6x
MNPR ██% $794M x 5.9x
MPLT ██% $585M x 1.5x
MREO ██% $51M x 1.5x
MRK ██% $316.42B 35.4x 6.9x
MRKR ██% $21M x 1.5x
MRVI ██% $2.37B x 11.2x
MSLE ██% $209M x x
MTNB ██% $2M x 0.6x
MTVA ██% $8M x 0.8x
NAMS ██% $3.21B x 4.8x
NATR ██% $359M 18.1x 2.2x
NBP ██% $191M x 0.7x
NBTX ██% $1.91B x x
NCEL ██% $19M x 34.3x
NCNA ██% $6M x x
NERV ██% $177M x x
NEUP ██% $21M x 0.7x
NGNE ██% $686M x 2.9x
NIKA ██% $535M x x
NKTR ██% $2.46B x 4.3x
NKTX ██% $168M x 0.6x
NMAD ██% $68M x 8.6x
NNVC ██% $39M x 4.2x
NRIX ██% $2.56B x 6.4x
NRSN ██% $19M x x
NRXP ██% $131M x x
NSRX ██% $41M x 14.8x
NTHI ██% $85M x x
NUVB ██% $2.23B x 7.0x
NUVL ██% $9.75B x 8.3x
NVCT ██% $655M x 72.1x
NVS ██% $292.46B x x
NWBO ██% $257M x x
NXTC ██% $24M x 0.9x
NXTS ██% $3M x 0.2x
OCUL ██% $1.89B x 3.6x
OGEN ██% $2M x 0.4x
OGI ██% $140M x x
OGN ██% $3.56B 17.0x 3.5x
OKUR ██% $166M x 1.0x
OLMA ██% $1.03B x 2.1x
OMER ██% $932M 10.8x x
ONC ██% $33.51B 51.1x 6.5x
ONCO ██% $3M x 0.3x
ONCY ██% $94M x x
OPK ██% $989M x 0.8x
ORGO ██% $305M 112.2x 1.3x
ORIC ██% $1.40B x 3.7x
ORKA ██% $5.92B x 12.2x
ORMP ██% $183M 1.7x 0.8x
OSTX ██% $74M x x
OTLC ██% $18M x 0.1x
OVID ██% $474M x 2.4x
OWPC ██% $110K x x
PAHC ██% $1.48B 15.6x 4.1x
PBH ██% $2.52B 13.2x 1.3x
PBM ██% $12M x x
PBYI ██% $397M 16.3x 3.1x
PCRX ██% $1.10B 75.1x 1.6x
PCSA ██% $6M x 2.2x
PCYN ██% $2M x 1.0x
PDSB ██% $40M x 10.3x
PEPG ██% $133M x 1.0x
PFE ██% $144.81B 33.4x 1.7x
PGEN ██% $2.34B x 53.7x
PHAT ██% $677M x x
PHIO ██% $12M x 0.8x
PHVS ██% $2.37B x x
PKTX ██% $3M x 10.8x
PLRX ██% $65M x 0.4x
PLYX ██% $106M x 42.4x
PMHS ██% $4M x x
PMN ██% $122M x 2.0x
PMVP ██% $62M x 0.7x
PPBT ██% $1M x x
PPCB ██% $2M x 0.2x
PRAX ██% $8.64B x 6.1x
PRFX ██% $3M x 0.4x
PRGO ██% $1.49B x 0.6x
PRLD ██% $373M x 6.2x
PRPH ██% $700K x 0.1x
PRQR ██% $258M x x
PRTA ██% $455M x 1.5x
PTCT ██% $5.76B x x
PTGX ██% $8.72B x 13.3x
PTIX ██% $410K x x
PTN ██% $14M x 1.3x
PTPI ██% $130K 0.0x 0.1x
PULM ██% $6M x 1.7x
PVCT ██% $24M x x
PVLA ██% $2.21B x 10.2x
PYXS ██% $203M x 6.5x
QNRX ██% $9M x 1.0x
QNTM ██% $18M x x
QTTB ██% $480M 14.2x 4.5x
QUCY ██% $34M x 7.4x
QURE ██% $2.75B x 18.4x
RADX ██% $23M x x
RANI ██% $113M x 4.0x
RAPP ██% $2.02B x 4.8x
RARE ██% $2.54B x x
RCKT ██% $375M x 1.6x
RCUS ██% $3.66B x 7.0x
RDY ██% $10.10B x x
REGN ██% $78.20B 18.1x 2.5x
REVB ██% $4M x 0.3x
RFL ██% $97M x 1.3x
RGBP ██% $80K x x
RIGL ██% $778M 2.4x 1.8x
RKTO ██% $20M x 4.9x
RLMD ██% $574M x 2.6x
RLYB ██% $84M x 1.7x
RMHI ██% $25M x x
RMTI ██% $30M x 0.8x
RNAC ██% $230M x x
RNAZ ██% $5M x 3.8x
RNTX ██% $65M x 5.6x
RNXT ██% $47M x 4.2x
ROIV ██% $25.07B x 5.5x
RPRX ██% $33.10B 40.0x 4.8x
RTEZ ██% $1.93B x x
RVPH ██% $7M x 0.4x
RVRC ██% $101M x 16.5x
RYTM ██% $7.28B x 70.7x
RZLT ██% $479M x 4.1x
SBFM ██% $3M x 0.1x
SCNX ██% $15M x 0.2x
SCYX ██% $429M x 10.4x
SDEV ██% $53M 0.1x 0.4x
SDGR ██% $1.16B x 3.7x
SEPN ██% $1.75B x 4.6x
SER ██% $32M x 1.8x
SGMT ██% $493M x 4.8x
SHPH ██% $3M x 0.8x
SIGA ██% $226M 11.2x 1.5x
SILO ██% $5M x 0.9x
SION ██% $2.24B x 7.8x
SKVI ██% $970K x x
SKYE ██% $21M x 2.3x
SLGL ██% $274M x 12.0x
SLN ██% $528M x 10.7x
SLS ██% $2.09B x 19.5x
SMMT ██% $10.80B x 17.2x
SMNR ██% $200M x x
SNDX ██% $1.72B x 114.2x
SNGX ██% $6M x 1.8x
SNSE ██% $31M x x
SNY ██% $104.47B x x
SPRB ██% $128M x 3.7x
SPRC ██% $4M x x
SPRO ██% $73M 4.8x 1.4x
SPRY ██% $539M x 8.8x
SRPT ██% $1.75B 27.0x 1.2x
STOK ██% $2.02B x 5.9x
STTK ██% $737M x 7.7x
SUPN ██% $2.72B x 2.6x
SVRA ██% $1.13B x 6.4x
SXTP ██% $3M x 0.7x
SYBX ██% $13M x 1.1x
SYRE ██% $9.17B x 8.3x
TAK ██% $53.22B x x
TBPH ██% $869M 7.6x 3.0x
TCRT ██% $5M x 3.5x
TELO ██% $84M x 16.9x
TENX ██% $496M x 4.4x
TEVA ██% $40.55B 57.4x 5.2x
TGTX ██% $7.56B 16.4x 13.0x
TLPH ██% $69M x 3.8x
TLX ██% $3.55B x x
TNGX ██% $4.70B x 12.0x
TNXP ██% $180M x 0.8x
TOVX ██% $10M x 0.7x
TPST ██% $14M x 17.6x
TRDA ██% $282M x 1.2x
TRVI ██% $2.41B x 14.0x
TTRX ██% $269M x 44.0x
TVRD ██% $18M x 1.2x
TVTX ██% $5.17B x 52.4x
TXMD ██% $24M 131.9x 0.9x
TYRA ██% $1.55B x 4.4x
UNCY ██% $130M x 3.5x
UPB ██% $367M x 1.2x
URGN ██% $2.16B x x
UTHR ██% $25.91B 20.1x 4.4x
VBIO ██% $1M x 0.1x
VCNX ██% $2M x x
VERA ██% $2.23B x 4.5x
VGLS ██% $240K x x
VICP ██% $47M x x
VKTX ██% $3.88B x 9.5x
VNDA ██% $307M x 1.1x
VRCA ██% $94M x 5.8x
VRDN ██% $2.06B x 3.2x
VREOD ██% $491M x 1.7x
VREOF ██% $491M x 1.7x
VRTX ██% $121.90B 27.7x 6.0x
VSTM ██% $509M x 6.2x
VTGN ██% $13M x 0.4x
VTRS ██% $20.36B x 1.4x
VYNE ██% $19M x 0.8x
WHWK ██% $195M x 1.7x
WVE ██% $1.15B x 2.5x
XBIO ██% $6M x 0.9x
XBIT ██% $69M x 0.5x
XCUR ██% $10M x 4.8x
XENE ██% $6.15B x 4.6x
XERS ██% $1.43B 118.7x 109.6x
XLO ██% $60M x 0.8x
XNCR ██% $1.49B x 2.9x
XOMA ██% $710M 21.0x 7.7x
XTLB ██% $7M x x
ZBIO ██% $1.94B x 5.8x
ZLAB ██% $2.08B x 3.1x
ZNTL ██% $337M x 1.9x
ZTS ██% $31.95B 12.1x 9.9x
ZVRA ██% $608M 4.9x 3.0x
ZVSA ██% $1M x x
Reveal all forecasts See exact % predictions for all competitors
Sign up free

Frequently Asked Questions - Generate Biomedicines, Inc. Stock Forecast

How accurate are Generate Biomedicines, Inc. stock predictions?

Our AI model shows a 8500% Spearman correlation coefficient for GENB predictions, based on advanced machine learning algorithms trained on over 10 years of market data. This measures the strength of the monotonic relationship between predicted and actual price movements.

What factors influence Generate Biomedicines, Inc. stock price forecasts?

Our analysis considers Generate Biomedicines, Inc.'s financial metrics, Life Sciences sector trends, market sentiment, technical indicators, earnings data, and macroeconomic factors affecting stock performance.

Is Generate Biomedicines, Inc. a good investment in 2025?

Based on our AI analysis, Generate Biomedicines, Inc. shows potential for various market scenarios. Consider your risk tolerance, investment timeline, and portfolio diversification before making investment decisions.

How often are Generate Biomedicines, Inc. forecasts updated?

Generate Biomedicines, Inc. stock forecasts are updated daily using real-time market data, ensuring you receive the most current AI-powered predictions and investment insights.

Want a simpler view of Generate Biomedicines, Inc.?

View simplified analysis on AI Stock Finder →

My Portfolio

Investment Dashboard

Loading your portfolio...